Dhanya Dharman | Pharmacology | Best Research Article Award

Published on by Best Paper Awards

Best Research Article Award

Dhanya Dharman
Dr Moopens College of Pharmacy, India
Paper Title: Effectiveness of mometasone, indacaterol, glycopyrronium (once daily single inhaler triple therapy) in the management of severe asthma: a prospective observational study

Dhanya Dharman
Affiliation Dr Moopens College of Pharmacy
Country India
Documents 53
Citations 37
h-index 4
Subject Area Pharmacology
Event International Research Excellence and Best Paper Awards
Google Scholar GausjtcAAAAJ&hl=en

Dhanya Dharman is a researcher affiliated with Dr Moopens College of Pharmacy, India, whose scholarly record includes 53 documents and 37 citations, with a reported h-index of 4. The research profile is situated within pharmacology and includes work examining therapeutic approaches for severe asthma, including single-inhaler triple therapy. [1]

Abstract

Dhanya Dharman is a pharmacology researcher affiliated with Dr Moopens College of Pharmacy in India. Her documented research profile comprises 53 scholarly documents, 37 citations, and an h-index of 4. A relevant research contribution examines the effectiveness of mometasone, indacaterol, and glycopyrronium, administered once daily through a single inhaler, for managing severe asthma. The prospective observational study addresses clinical treatment effectiveness within a real-world patient context and contributes to evidence concerning inhaled corticosteroid, long-acting beta2-agonist, and long-acting muscarinic antagonist combinations. The work reflects an applied pharmacological perspective focused on therapeutic management, treatment response, and respiratory disease care. [1]

Keywords

Severe asthma; triple therapy; mometasone; indacaterol; glycopyrronium; inhaler therapy; pharmacology; respiratory medicine; prospective observational study; asthma management.

Introduction

Severe asthma can require intensified pharmacological management when conventional treatment does not provide adequate control. Inhaled corticosteroids combined with long-acting bronchodilators are established therapeutic approaches, while triple therapy adds a long-acting muscarinic antagonist. The submitted study investigates this combination in a prospective observational setting. [1]

Research Profile

The supplied bibliometric record identifies 53 documents, 37 citations, and an h-index of 4 for Dhanya Dharman. These indicators provide a quantitative description of indexed scholarly output and citation activity, although bibliometric measures should be interpreted alongside publication quality, research context, authorship, and field-specific citation practices. [1]

Research Contributions

The principal research contribution identified for this recognition concerns the prospective observational assessment of once-daily single-inhaler triple therapy containing mometasone, indacaterol, and glycopyrronium. The study focuses on severe asthma management and provides clinical observations relevant to evaluating combined inhaled pharmacotherapy in routine treatment environments. [2]

Publications

The supplied record reports 53 documents associated with the researcher. The specifically identified paper is titled Effectiveness of mometasone, indacaterol, glycopyrronium (once daily single inhaler triple therapy) in the management of severe asthma: a prospective observational study. Complete bibliographic metadata, including journal, publication year, DOI, and author list, was not supplied and should therefore be verified before formal citation. [1]

Research Impact

The reported 37 citations indicate that the research output has received scholarly references in subsequent literature. Citation counts are indicators of academic visibility rather than direct measures of clinical effectiveness or societal benefit. The identified asthma research may be relevant to discussions of inhaled triple therapy and severe respiratory disease management. [1]

Award Suitability

The documented research aligns with the academic scope of a Best Research Article Award through its focus on a defined pharmacological intervention and a clinically relevant respiratory condition. Consideration may include methodological design, clarity of objectives, evidence quality, originality, relevance to pharmacology, and the completeness of supporting publication documentation. [2]

Conclusion

Dhanya Dharman’s supplied research profile documents scholarly activity in pharmacology and includes research addressing severe asthma treatment. The identified prospective observational study examines once-daily single-inhaler triple therapy involving mometasone, indacaterol, and glycopyrronium. Its subject focus provides a relevant basis for academic recognition within pharmacological and respiratory research. [1]

References

    1. Ramesan, R. (n.d.). Google Scholar profile. Google Scholar.
      Google Scholar Profile

    2. The era of pharmacovigilance and the need of pharmacovigilance in psychiatry: A review.
      https://www.researchgate.net/publication/331268791_The_era_of_pharmacovigilance_and_the_need_of_pharmacovigilance_in_psychiatry_A_review

    3. A cross sectional study of polycystic ovarian syndrome among pharmacy students.
      https://www.researchgate.net/publication/339282966_A_cross_sectional_study_of_polycystic_ovarian_syndrome_among_pharmacy_students

Dr. Kakali Purkayastha | Pharmacology | Research Excellence Award

Published on by Best Paper Awards

Dr. Kakali Purkayastha | Pharmacology | Research Excellence Award

Consultant | ICMR HeadQuarters | India

Dr. Kakali Purkayastha is a researcher known for contributions to interdisciplinary scientific studies, with a professional record spanning academic and applied research environments. Her professional experience includes collaborative projects, publications, and mentoring roles that reflect scholarly engagement. Her research interests focus on scientific domains, emphasizing innovation and practical impact. She possesses research skills in data analysis, experimental design, and scientific communication. Her awards and honors recognize excellence and dedication to research advancement. Overall, her work demonstrates commitment to knowledge development and impactful scholarship. She has achieved 98 Citations, 4 Documents, 4 h-index.

Citation Metrics (Scopus)

100
50
0

98
Citations

4
Documents

4
h-index

Citations

Documents

h-index

View Scopus Profile

Featured Publications

Paula Abola | Pharmacology | Editorial Board Member

Published on by Best Paper Awards

Mrs. Paula Abola | Pharmacology | Editorial Board Member

PhD Student and Professor | University of Jamestown | Germany

Paula Abola is an emerging clinical research scholar whose academic and scientific contributions reflect a strong interdisciplinary foundation in medicinal chemistry, drug development, and neurodegenerative disease research, particularly Parkinson’s disease. She is currently pursuing a PhD in Clinical Research at the University of Jamestown, building on her Master of Science in Clinical Drug Development from Queen Mary University of London and her Bachelor of Science in Medicinal Chemistry and Chemical Biology from Jacobs University Bremen. Her research portfolio demonstrates a growing specialization in movement disorders, with multiple peer-reviewed publications addressing both pharmacological and non-pharmacological management of Parkinson’s disease. Her work includes systematic reviews and meta-analyses evaluating key therapeutic agents such as liquid subcutaneous levodopa-carbidopa (ND0612), rasagiline, and safinamide, focusing on their effects on motor and non-motor symptoms as well as adverse event profiles. Additionally, she has explored innovative technological methodologies for detecting, quantifying, and reducing Parkinsonian tremor, highlighting her interest in rehabilitative and assistive approaches. Abola has also investigated sociodemographic influences on patient and clinician understanding of treatment pathways, contributing meaningful insights into healthcare accessibility, knowledge disparities, and patient-centered care. Her publication on intra-individual variations in voice parameters among individuals with and without Parkinson’s disease further expands her scope into speech-related biomarkers, emphasizing her multidimensional approach to disease assessment. Across her eight documented works, she collaborates frequently with researchers such as Kristin Lefebvre, Mitchell Wolden, and Benjamin Wolden, demonstrating strong engagement in team-based research environments. Overall, Paula Abola’s academic trajectory and scholarly output position her as a dedicated early-career researcher committed to advancing therapeutic strategies, improving diagnostic tools, and deepening understanding of patient experiences within the field of Parkinson’s disease clinical research.

Profile: ORCID

Featured Publications

  1. Abola, P., Lefebvre, K., & Wolden, M. (2025). Influence of sociodemographic variables on patient and practitioner knowledge of pharmacological management options for Parkinson’s disease. American Journal of Medical and Clinical Research & Reviews, 2025.

  2. Abola, P., Lefebvre, K. (2025). Technological advancements in the detection and quantification of Parkinsonian tremor. Topics in Geriatric Rehabilitation, July 2025.

  3. Abola, P., Wolden, M. (2025). Intra-individual variations in voice variables among individuals with and without Parkinson’s disease. Cureus, March 29, 2025.

  4. Abola, P., Wolden, M., & Lefebvre, K. (2024). Liquid subcutaneous levodopa-carbidopa ND0612 effects on motor symptoms in individuals with Parkinson’s disease: A systematic review and meta-analysis. Advances in Parkinson’s Disease, 2024.

  5. Abola, P., Wolden, M. (2024). Monoamine oxidase-B inhibitor rasagiline effects on motor and non-motor symptoms in individuals with Parkinson’s disease: A systematic review and meta-analysis. Advances in Parkinson’s Disease, 2024.

Paula Abola’s research advances the understanding and treatment of Parkinson’s disease by integrating clinical evidence, therapeutic evaluation, and emerging diagnostic technologies. Her work contributes to more precise, accessible, and patient-centered care, strengthening global efforts to improve quality of life for individuals with neurodegenerative disorders. She envisions a future where innovative clinical tools and evidence-based interventions enable earlier detection, optimized treatment, and equitable management of neurological conditions worldwide.

Luisa Pozzo | Pharmacology | Excellence in Research Award

Published on by Best Paper Awards

Assoc. Prof. Dr. Luisa Pozzo | Pharmacology | Excellence in Research Award 

Senior Researcher | IBBA-CNR | Italy

Assoc. Prof. Dr. Luisa Pozzo is a distinguished senior researcher with over fifteen years of continuous, high-impact contributions to food science, toxicology, nutraceuticals, and preclinical disease models, currently serving at the National Research Council of Italy through the Institute of Agricultural Biology and Biotechnology. Her internationally recognized expertise lies in the biofunctional characterization of food products, oxidative stress, inflammation, nonalcoholic fatty liver disease, neurodegeneration, and novel food safety using validated mouse and rat models, with strong relevance to human health and predictive toxicology. She has authored more than 45 peer-reviewed publications in prestigious Q1 journals including Food Chemistry, Nutrients, Antioxidants, Molecules, Scientific Reports, and Food and Chemical Toxicology, reflecting exceptional productivity, quality, and global scientific influence. As Principal Investigator and scientific referent for multiple competitive national and international projects funded by the Italian Ministry of University and Research, Horizon Europe, regional authorities, and bilateral collaborations with Poland, Egypt, and Slovakia, she has demonstrated outstanding leadership in translational and multidisciplinary research. Her academic service includes long-standing editorial roles as Section Editor of the Polish Journal of Food and Nutrition Sciences, Topic Editor of Frontiers in Toxicology, and Guest Editor of Foods. She is also a committed educator and mentor, having taught Applied Nutraceuticals for nearly a decade at the University of Pisa while supervising PhD, postdoctoral, and postgraduate researchers internationally. Her consistent scientific excellence, grant leadership, editorial influence, mentoring impact, and translational outcomes firmly establish her as a highly deserving candidate for an Excellence in Research Award.

Profiles: Google Scholar | Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

  1. Trouki, C., Campanella, B., Onor, M., Vornoli, A., Pozzo, L., Longo, V., & Bramanti, E. (2024). Probing the alterations in mice cecal content due to high-fat diet. Food Chemistry, 430, 139856.

  2. Souid, A., Giambastiani, L., Castagna, A., Santin, M., Vivarelli, F., Canistro, D., Morosini, C., Paolini, M., Franchi, P., Lucarini, M., Raffaelli, A., Giorgetti, L., Ranieri, A., Longo, V., Pozzo, L., & Vornoli, A. (2024). Assessment of the antioxidant and hypolipidemic properties of Salicornia europaea for the prevention of TAFLD in rats. Antioxidants, 13(5), 596.

  3. Wijaya, G. Y. A., Vornoli, A., Giambastiani, L., Digiacomo, M., Macchia, M., Szymczak, B., Wójcik, M., Pozzo, L., & Longo, V. (2025). Solid-state fermented cereals: Increased phenolics and their role in attenuating liver diseases. Nutrients, 17(5), 900.

  4. Tancreda, G., Campisi, L., Sarti, M., Pozzo, L., & Vornoli, A. (2025). Perfluoroalkyl substances (PFAS) and lipid metabolism in experimental animal models: A scoping review on the mechanisms behind the induced hepatotoxicity. Current Issues in Molecular Biology, 47(11), 0000.

  5. Amin, A. A., Mahmoud, K. F., Salama, M. F., Longo, V., Pozzo, L., Seliem, E. I., & Ibrahim, M. A. (2023). Characterization and stability evaluation of Egyptian propolis extract nano-capsules and their application. Scientific Reports, 13, 42025.

Assoc. Prof. Dr. Luisa Pozzo’s research advances global understanding of how bioactive foods and nutraceuticals can prevent chronic diseases through precise preclinical and toxicological validation. Her work bridges fundamental science with food safety, sustainable nutrition, and human health, driving innovation across academia, industry, and public health sectors.

D Chandra Sekhar Naik | Pharmacology | Best Researcher Award

Published on by Best Paper Awards

Dr. D Chandra Sekhar Naik | Pharmacology | Best Researcher Award

Professor at Nimra College of Pharmacy, India

Dr. D Chandra Sekhar Naik is an accomplished pharmaceutical researcher with expertise in pharmaceutics, advanced drug delivery systems, and formulation development of poorly soluble drugs. He earned his Ph.D. focusing on fast-dissolving tablets using novel natural superdisintegrants and has actively contributed to high-impact research projects, including DST SERB-funded studies. Dr. Naik has an extensive publication record in reputed journals and conferences, demonstrating his innovative approach to drug formulation and optimization. He has guided numerous B.Pharmacy and M.Pharmacy research projects, reflecting his dedication to mentoring emerging researchers. Beyond research, he holds leadership positions as Professor and HOD, participates in academic councils, and engages in community initiatives such as NSS programs and National Pharmacy Week. With professional memberships and advanced technical proficiency, he exemplifies excellence in research, education, and societal contribution.

Professional Profile

Google Scholar | Scopus Profile | Orcid Profile

Education

Dr. D Chandra Sekhar Naik holds a Ph.D. in Pharmaceutics from KVSR Siddhartha College of Pharmaceutical Research Center, Krishna University, where his research focused on designing, optimizing, and evaluating fast-dissolving tablets of poorly soluble BCS-II drugs using novel natural superdisintegrants. He also holds a Master’s degree in Pharmaceutics and a Bachelor’s degree in Pharmacy, which provided him with a strong foundation in pharmaceutical sciences, drug formulation, and delivery systems. His academic training included extensive research on enhancing drug solubility and dissolution rates using innovative techniques such as liquisolid systems and complexation methods. Throughout his academic journey, he demonstrated a strong aptitude for both theoretical knowledge and practical applications in pharmaceutical research, establishing a robust framework for his subsequent contributions to formulation development, biopharmaceutics, pharmacokinetics, and advanced drug delivery systems.

Professional Experience

Dr. Naik has a distinguished career in pharmaceutical academia and research, holding positions from Assistant Professor to Professor and Head of Department at Nimra College of Pharmacy. He has taught a wide range of subjects including advanced physical pharmacy, pharmacokinetics, biopharmaceutics, and drug delivery systems at both undergraduate and postgraduate levels. He has served as a member of academic councils and boards of studies, contributing to curriculum development and academic governance. Beyond teaching, he has acted as an external examiner and evaluator for multiple universities, demonstrating his expertise in assessing research quality. His leadership extends to coordinating student activities, mentoring research projects, and guiding professional development, establishing a comprehensive impact on both academic and research environments.

Research Interest

Dr. Naik’s research interests encompass advanced drug delivery systems, formulation development of poorly soluble drugs, chronotherapeutics, and the design of fast-dissolving tablets using natural and synthetic superdisintegrants. He focuses on improving solubility, dissolution rates, and bioavailability of pharmaceutical compounds through innovative approaches such as liquisolid systems, multiparticulate formulations, and controlled-release technologies. His work integrates pharmaceutical chemistry, pharmacokinetics, and biopharmaceutics to develop therapeutically effective and patient-friendly dosage forms. Additionally, he is interested in exploring novel polymers and excipients for enhanced drug delivery, as well as evaluating in vitro and in vivo performance of formulations. His research aims to bridge the gap between scientific innovation and clinical applicability, contributing to both academic knowledge and societal healthcare improvements.

Award and Honor

Dr. Naik has received recognition for his contributions to pharmaceutical research and education through multiple awards, honors, and professional appointments. He has been invited to present his work at national and international conferences and workshops, reflecting his leadership in the field. He holds patents and copyrights for innovative pharmaceutical technologies and has served as a reviewer for reputable journals, highlighting his credibility in the academic community. His dedication to mentoring students and coordinating community-focused initiatives, such as National Pharmacy Week activities, underscores his commitment to professional excellence and societal impact. These accolades and responsibilities collectively affirm his status as a leading researcher and educator in pharmaceutical sciences.

Research Skill

Dr. Naik possesses comprehensive research skills in pharmaceutical formulation, analytical techniques, and experimental design. He is proficient in high-performance liquid chromatography, UV-VIS spectroscopy, dissolution testing, and advanced pharmaceutical product optimization software. His expertise extends to formulation and evaluation of fast-dissolving tablets, oral disintegrating systems, bilayer tablets, and chronotherapeutic dosage forms. He demonstrates strong competence in designing experiments using factorial and quality-by-design approaches, ensuring reproducibility and accuracy in research outcomes. Additionally, he excels in mentoring students, guiding them through research methodology, project execution, and scientific writing. His skills are complemented by a strong publication record, collaborative research experience, and familiarity with regulatory and professional standards, reflecting a well-rounded capability to drive impactful pharmaceutical research.

Publication Top Notes

Title: Development And Validation Of Estimation Of Doxofylline Pharmaceutical Dosage Forms By Rp-Hplc Method
Authors: Md Imran Khan, Reshma Kaja, Chandra Sekhar Naik D, M Janarthan
Year: 2025
Citation: Vytapeni, Vetrani, Instalace. 13(6): June 2025

Title: Method Development and Validation of Crizotinib Pharmaceutical Formulation by Using Rp-Hplc
Authors: Thota Silpa, M Venkata Kumari, Chandra Sekhar Naik D, M Janarthan
Year: 2025
Citation: Vytapeni, Vetrani, Instalace. 13(6): June 2025

Title: Method Development and Validation of Isoniaizid and Atazanavir
Authors: Janga Keerti Rani, M Venkata Kumari, Chandra Sekhar Naik D, M Janarthan
Year: 2025
Citation: Vetrani, Instalace. 13(6): June 2025

Title: Method Development and Validation of Losartan Potassium and Amlodipine Besylate in Tablet Dosage Form by Rp-Hplc Method
Authors: Tanvir Alam, Reshma Kaja, Chandra Sekhar Naik D, M Janarthan
Year: 2025
Citation: Vytapeni, Vetrani, Instalace. 13(6): June 2025

Title: Formulation And Evaluation of Aspirin Emulgel using Natural Permeation Enhancers
Authors: Shaik Abdul Rehman, Shaik Jafar Ali, Chandra Sekhar Naik D, M Janarthan, K Uday Kiran, Md Zulekha
Year: 2026
Citation: Research Journal of Pharmacy and Technology. 19(2)

Title: Formulation And Evaluation of Diclofenac Emulgel Using Natural Permeation Enhancers
Authors: Shaik Noor Mahammed, Mudigedu Samreen, Chandra Sekhar Naik D, S Vamsi, P Hemalatha
Year: 2025
Citation: Journal of Applied Pharmaceutical Research. 13(2)

Title: Formulation and Evaluation of Rhamnolipids-Based Ternary Solid Dispersion System for Poorly Soluble Drug
Authors: Sai Sindhu Ponnathota, Chandra Sekhar Naik D
Year: 2025
Citation: Research Journal of Pharmacy and Technology. 18(10)

Title: Short Term-Subacute and Chronic Toxicity Studies on The Mucilage of Plantago Ovata, A Novel Natural Compound Administered by Oral in Wistar Rats
Authors: Chandra Sekhar Naik D, Shaik Abdul Rehman, Shaik Jafar Ali, K Uday Kiran, Md Zulekha
Year: 2025
Citation: Research Journal of Pharmacy and Technology. 18(7)

Title: Pharmacokinetics evaluation of telmisartan chronotherapeutic press coated tablets
Authors: Bharathi Arigela, Chandra Sekhar Naik D, Kovida Chanumolu, Yamani Durga Talaparthi
Year: 2025
Citation: Research Journal of Pharmacy and Technology. 18(1)

Title: Formulation and evaluation of fast dissolving tamoxifen citrate tablets for breast cancer
Authors: K Suneela Grace, Ch Vidyulatha, Chandra Sekhar Naik D, Janarthan M
Year: 2024
Citation: Frontiers Health Informatics. 13(6): 921–931

Title: Development And In Vitro Evaluation of Aceclofenac Mouth Dissolving Films for Reduced Analgesic Activity
Authors: Chandra Sekhar Naik D, Bharathi Arigela, Venkata Suresh Babu Agala, Cherukuri Vidyulatha Chowdary
Year: 2024
Citation: Journal of Applied Pharmaceutical Research. 12(5)

Title: Design and Evaluation of Fast Dissolving Tablets of Anti-Hypertensive Poorly Soluble Drug through 2³ Factorial Designs
Authors: Chandra Sekhar Naik D, Bharathi Arigela, Venkata Suresh Babu Agala, Shabana Parveen
Year: 2024
Citation: International Journal of Drug Delivery Technology. 14(4)

Title: In-Vivo Studies of Optimized Fast Dissolving Tablets of Non-Steroidal Anti-Inflammatory Drug Employing Natural Mucilage
Authors: Chandra Sekhar Naik D, Bharathi Arigela, Venkata Suresh Babu Agala, Shabana Parveen, Cherukuri Vidyulatha Chowdary
Year: Under review
Citation: International Journal of Advancement in Life Sciences Research

Title: Formulation and Development of Ambroxol Hydrochloride Syrup
Authors: D Chandra Sekhar Naik, A Yamini Madhu Latha, B Harshitha
Year: 2023
Citation: International Journal of Pharmaceutical Research and Applications. 8(1)

Title: Design And Evaluation Of Fast Dissolving Tablets Using A Novel Natural Superdisintegrant
Authors: D Chandra Sekhar Naik, A Bharathi
Year: 2023
Citation: Research Journal of Pharmacy and Technology. 16(4)

Title: Pharmacokinetic Studies of A Poorly Soluble BCS Class II Non Steroidal Anti Inflammatory Drug in Oral Formulations
Authors: D Chandra Sekhar Naik, A Bharathi
Year: 2022
Citation: International Journal of Pharmaceutical Research and Applications. 7(5)

Title: Full Factorial Designs for Formulation and Evaluation of Non Steroidal Anti-inflammatory Drug
Authors: Desavath C S Naik, Arigela Bharathi
Year: 2022
Citation: International Journal of Drug Delivery Technology. 12(1)

Title: Studies On Design And Development Of Dissolvable Oral Drug Delivery Systems Of A Poorly Water Soluble Non-Steroidal Anti-Inflammatory Drug
Authors: T Sukanya, S Srivallika, D Chandra Sekhar Naik
Year: 2022
Citation: European Journal Of Pharmaceutical And Medical Research. 8(12)

Title: Design, Optimization And Evaluation Of Telmisartan Chronotherapeutics Press Coated Tablets Employing Novel Natural Superdisintegrant And Novel Coated Chronotherapeutic Polymers
Authors: A Bharathi, D Chandra Sekhar Naik
Year: 2021
Citation: International Journal of Pharmaceutical Sciences and Research (IJPSR). 12(3)

Title: Design, Optimization and Evaluation of Telmisartan Chronotherapeutics Press Coated Tablets Employing Novel Synthetic Disintegrant and Novel Coated Chronotherapeutic Polymers
Authors: A Bharathi, D Chandra Sekhar Naik
Year: 2021
Citation: Research Journal of Pharmacy and Technology. 14(3)

Conclusion

Dr. D Chandra Sekhar Naik is a highly accomplished pharmaceutical researcher whose contributions span innovative formulation development, advanced drug delivery systems, and mentoring future researchers. His academic and professional experience, coupled with a robust publication record and research expertise, highlights his dedication to advancing pharmaceutical sciences. He demonstrates leadership in both educational and research settings, engaging actively in community initiatives and professional organizations. His work has direct societal impact through improved drug therapies and patient outcomes. With a proven ability to integrate scientific innovation with practical application, Dr. Naik exhibits strong potential for continued leadership, global collaborations, and groundbreaking research that will further enhance the field of pharmaceutical sciences.